Apogee Therapeutics Inc. (APGE)
34.98
-2.85 (-7.53%)
At close: Apr 03, 2025, 3:59 PM
34.50
-1.36%
Pre-market: Apr 04, 2025, 04:33 AM EDT
-7.53% (1D)
| Bid | 33.38 |
| Market Cap | 2.08B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.3 |
| PE Ratio (ttm) | -10.6 |
| Forward PE | -9.87 |
| Analyst | Buy |
| Ask | 42 |
| Volume | 632,351 |
| Avg. Volume (20D) | 682,048.2 |
| Open | 36.38 |
| Previous Close | 37.83 |
| Day's Range | 33.58 - 36.45 |
| 52-Week Range | 29.10 - 63.50 |
| Beta | 1.73 |
About APGE
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs inclu...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 14, 2023
Employees 196
Stock Exchange NASDAQ
Ticker Symbol APGE
Analyst Forecast
According to 5 analyst ratings, the average rating for APGE stock is "Buy." The 12-month stock price forecast is $89.5, which is an increase of 155.90% from the latest price.
Stock Forecasts4 months ago
-5.14%
Apogee Therapeutics shares are trading lower. The ...
Unlock content with
Pro Subscription
7 months ago
+10.59%
Apogree Therapeutics shares are trading higher after the company announced its initiated dosing of its clinical trail for APG990.
